Potential of Toll-like receptor 9 agonists in combined anticancer immunotherapy strategies: synergy of PAMPs and DAMPs?
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Potential of Toll-like receptor 9 agonists in combined anticancer immunotherapy strategies: synergy of PAMPs and DAMPs?
Authors
Keywords
-
Journal
Immunotherapy
Volume 3, Issue 3, Pages 301-304
Publisher
Future Medicine Ltd
Online
2011-03-11
DOI
10.2217/imt.10.118
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Surface-exposed calreticulin in the interaction between dying cells and phagocytes
- (2010) Isabelle Martins et al. Annals of the New York Academy of Sciences
- In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
- (2010) Joshua D. Brody et al. JOURNAL OF CLINICAL ONCOLOGY
- Expression of calreticulin is associated with infiltration of T-cells in stage IIIB colon cancer
- (2010) Rui-Qing Peng WORLD JOURNAL OF GASTROENTEROLOGY
- Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma
- (2009) Jeffrey S. Weber et al. CANCER
- Immunogenic death of colon cancer cells treated with oxaliplatin
- (2009) A Tesniere et al. ONCOGENE
- Therapeutic Targeting of Toll-Like Receptors for Infectious and Inflammatory Diseases and Cancer
- (2009) L. A. J. O'Neill et al. PHARMACOLOGICAL REVIEWS
- Route of Administration of the TLR9 Agonist CpG Critically Determines the Efficacy of Cancer Immunotherapy in Mice
- (2009) Stefan Nierkens et al. PLoS One
- Toll-like receptors: lessons to learn from normal and malignant human B cells
- (2008) D. Chiron et al. BLOOD
- Molecular Interactions between Dying Tumor Cells and the Innate Immune System Determine the Efficacy of Conventional Anticancer Therapies
- (2008) L. Apetoh et al. CANCER RESEARCH
- The B Cell Receptor Governs the Subcellular Location of Toll-like Receptor 9 Leading to Hyperresponses to DNA-Containing Antigens
- (2008) Akanksha Chaturvedi et al. IMMUNITY
- Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung Cancer
- (2008) Christian Manegold et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparative Proteomics Study Reveals That Bacterial CpG Motifs Induce Tumor Cell Autophagyin Vitroandin Vivo
- (2008) Samuel Bertin et al. MOLECULAR & CELLULAR PROTEOMICS
- UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomes
- (2008) You-Me Kim et al. NATURE
- Toll-like receptor 9 (TLR9) agonists in the treatment of cancer
- (2008) A M Krieg ONCOGENE
- TLR signaling by tumor and immune cells: a double-edged sword
- (2008) B Huang et al. ONCOGENE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started